February 24, 2020
1 min read

Upfront CART-BCMA with or without huCART19 in High-risk Multiple Myeloma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Phase 1, interventional, open-label study to assess the safety and pharmacodynamics of CART-BCMA, with or without huCART19, for patients responding to first- or second-line therapy for high-risk multiple myeloma.